Adverse Selection Risk for Monark

Adverse selection is the clearest way Monark could lose the market before it truly has it. In private markets, investors do not browse a catalog the way they buy public stocks. They come for a few specific names, then judge the whole platform by whether those names, or similarly strong products, are actually available. Monark itself frames top pre-IPO brands as the wedge, while also noting that subscale platforms often miss the best assets entirely.

• This is mainly a supply problem, not a demand problem. Monark says issuers care about distribution scale, and scale is what unlocks better SPVs and funds. Without that, weaker deals are more likely to accept platform distribution, which can train investors and brokerage partners to expect leftovers rather than must have inventory.
  1 sacra 2 sacra
• iCapital shows what the opposite of adverse selection looks like in practice. Its grip on wirehouses, feeder funds, diligence, and post-trade administration makes it useful to the biggest distributors and asset managers at the same time. That installed base helps it get product approved, cleared, and sold through the channels where most private wealth volume already sits.
  4 sacra 5 sacra 6 sacra
• The risk compounds because brokerage partners are buying economics as much as access. Monark can generate 2% to 3% commission economics for partners, but that only matters if the offerings actually pull investor demand. If investors show up hoping for SpaceX or OpenAI and see second tier inventory instead, the integration becomes harder for partners to market and defend.
  1 sacra 3 sacra 7 robinhood

The next phase is a race to turn distribution scale into supply quality before incumbents lock up the best product. If Monark keeps adding brokerage and RIA channels, it can use that reach to win stronger pre-IPO and evergreen fund inventory. If it does, the platform starts to look less like a fallback shelf and more like core private market infrastructure.